Готові списки джерел за темами / Coronary heart disease Victoria Prevention

Добірка наукової літератури з теми "Coronary heart disease Victoria Prevention"

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Coronary heart disease Victoria Prevention".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Coronary heart disease Victoria Prevention"

Rawstorn, Jonathan Charles, Kylie Ball, Brian Oldenburg, Clara K. Chow, Sarah A. McNaughton, Karen Elaine Lamb, Lan Gao, et al. "Smartphone Cardiac Rehabilitation, Assisted Self-Management Versus Usual Care: Protocol for a Multicenter Randomized Controlled Trial to Compare Effects and Costs Among People With Coronary Heart Disease." JMIR Research Protocols 9, no. 1 (January 27, 2020): e15022. http://dx.doi.org/10.2196/15022.

Повний текст джерела

Анотація:

Background Alternative evidence-based cardiac rehabilitation (CR) delivery models that overcome significant barriers to access and delivery are needed to address persistent low utilization. Models utilizing contemporary digital technologies could significantly improve reach and fidelity as complementary alternatives to traditional center-based programs. Objective The aim of this study is to compare the effects and costs of the innovative Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM) intervention with usual care CR. Methods In this investigator-, assessor-, and statistician-blinded parallel 2-arm randomized controlled trial, 220 adults (18+ years) with coronary heart disease are being recruited from 3 hospitals in metropolitan and regional Victoria, Australia. Participants are randomized (1:1) to receive advice to engage with usual care CR or the SCRAM intervention. SCRAM is a 24-week dual-phase intervention that includes 12 weeks of real-time remote exercise supervision and coaching from exercise physiologists, which is followed by 12 weeks of data-driven nonreal-time remote coaching via telephone. Both intervention phases include evidence- and theory-based multifactorial behavior change support delivered via smartphone push notifications. Outcomes assessed at baseline, 12 weeks, and 24 weeks include maximal aerobic exercise capacity (primary outcome at 24 weeks), modifiable cardiovascular risk factors, exercise adherence, secondary prevention self-management behaviors, health-related quality of life, and adverse events. Economic and process evaluations will determine cost-effectiveness and participant perceptions of the treatment arms, respectively. Results The trial was funded in November 2017 and received ethical approval in June 2018. Recruitment began in November 2018. As of September 2019, 54 participants have been randomized into the trial. Conclusions The innovative multiphase SCRAM intervention delivers real-time remote exercise supervision and evidence-based self-management behavioral support to participants, regardless of their geographic proximity to traditional center-based CR facilities. Our trial will provide unique and valuable information about effects of SCRAM on outcomes associated with cardiac and all-cause mortality, as well as acceptability and cost-effectiveness. These findings will be important to inform health care providers about the potential for innovative program delivery models, such as SCRAM, to be implemented at scale, as a complement to existing CR programs. The inclusion of a cohort comprising metropolitan-, regional-, and rural-dwelling participants will help to understand the role of this delivery model across health care contexts with diverse needs. Trial Registration Australian New Zealand Clinical Trials Registry (ACTRN): 12618001458224; anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374508. International Registered Report Identifier (IRRID) DERR1-10.2196/15022

Стилі APA, Harvard, Vancouver, ISO та ін.

King, Kathryn M., and Heather M. Arthur. "Coronary Heart Disease Prevention." Journal of Cardiovascular Nursing 18, no. 4 (September 2003): 274–81. http://dx.doi.org/10.1097/00005082-200309000-00006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rose, Geoffrey, M. P. H. Doublet Stewart, ChristopherA Birt, PeterR Croft, and PatrickF James. "CORONARY HEART DISEASE PREVENTION." Lancet 332, no. 8619 (November 1988): 1081–82. http://dx.doi.org/10.1016/s0140-6736(88)90102-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mccormick, JamesS, Petr Skrabanek, J. A. Lee, and R. C. Cottrell. "CORONARY HEART DISEASE PREVENTION." Lancet 332, no. 8621 (November 1988): 1189–90. http://dx.doi.org/10.1016/s0140-6736(88)90252-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Linden, B. "Coronary heart disease prevention." Coronary Health Care 3, no. 2 (May 1999): 99–104. http://dx.doi.org/10.1016/s1362-3265(99)80022-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Linden, Belinda. "Coronary heart disease prevention." Coronary Health Care 3, no. 1 (February 1999): 48–53. http://dx.doi.org/10.1016/s1362-3265(99)80034-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shakhnoza, Iskandarova, and Amilova Asalya. "PREVENTION OF CORONARY HEART DISEASE." American Journal of Medical Sciences and Pharmaceutical Research 04, no. 04 (April 1, 2022): 19–21. http://dx.doi.org/10.37547/tajmspr/volume04issue04-05.

Повний текст джерела

Анотація:

Primary prevention, based on healthy lifestyle habits that prevent the emergence of risk factors, is the preferred method of reducing cardiovascular risk. Reducing the prevalence of obesity is the most urgent task, and it is pleiotropic in that it affects blood pressure, lipid profile, glucose metabolism, inflammation, progression of atherothrombotic disease. Physical activity also improves several risk factors, with the added potential to lower heart rate.

Стилі APA, Harvard, Vancouver, ISO та ін.

Hulse, Iris M. "Prevention of Coronary Heart Disease." Journal of the Royal Society of Medicine 83, no. 10 (October 1990): 672. http://dx.doi.org/10.1177/014107689008301042.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Brooks, Gary. "Prevention of Coronary Heart Disease." Cardiopulmonary Physical Therapy Journal 4, no. 2 (1993): 17. http://dx.doi.org/10.1097/01823246-199304020-00005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Robin, Eugene D., and Robert K. McCauley. "Prevention of Coronary Heart Disease." Critical Care Medicine 23, no. 9 (September 1995): 1614–15. http://dx.doi.org/10.1097/00003246-199509000-00036.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Coronary heart disease Victoria Prevention"

Leong, Yuk-yan Pauline, and 梁玉恩. "The effectiveness of exercise-based cardiac rehabilitation program for secondary prevention of coronary heart disease : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193828.

Повний текст джерела

Анотація:

Objective: To examine the effect of exercise-based cardiac rehabilitation program for secondary prevention of coronary heart disease on cardiac-related mortality, recurrent cardiovascular event and quality of life. Methods: All studies published between 1990 and 2013 in PubMed, and from 1980 to 2013 in EMBASE, which evaluated the effectiveness of exercise-based cardiac rehabilitation program for coronary heart disease. Using the specific keywords “Cardiac rehabilitation”, “Coronary heart disease” OR “Ischemic heart disease” [MeSH], “Exercise” OR “Physical activities” AND “Quality of life” OR “Mortality” AND Cardiovascular events” were searched. A total of 7randomized controlled trials out of 5,051articles from PubMed and 117 articles from EMBASE were included in this systematic review. The primary outcome measures used in the included seven studies were HRQOL, restenosis, cardiac event, cardiac related mortality. Similar demographic and clinical characteristics of the subjects between the intervention and the control groups were recorded. The studies were from five countries. The average age of the subjects in the seven studies was 61years, the average half of them have history of myocardial infarction. Though there were discrepancies among the results generated in the included studies, the potential benefits of exercise-based cardiac rehabilitation could be seen. Results: Compared with the non-exercise-based cardiac rehabilitation, patients allocated to the exercise-based cardiac rehabilitation program had greater improvement in HRQOL and reduction of cardiac events. The result of reducing restenosis was inconsistent. The cardiac related mortality is not significant difference between exercise-based and non-exercise-based cardiac rehabilitation.
published_or_final_version
Public Health
Master
Master of Public Health

Стилі APA, Harvard, Vancouver, ISO та ін.

Ashton, Emma Louise, and emma ashton@deakin edu au. "Effects of dietary constituents on coronary heart disease risk factors." Deakin University. School of Biological and Chemical Sciences, 2000. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20061207.153511.

Повний текст джерела

Анотація:

Coronary Heart Disease (CHD) is a major cause of death in Western countries. Mediterranean and Asian populations have a lower risk of death from CHD compared to Westernised population, as do vegetarian versus omnivorous populations. Dietary constituents of traditional diets consumed by these populations are thought to influence both the classical risk factors for CHD, and the more recently identified risk factors, such as oxidative modification of low density lipoprotein (LDL), LDL particle size, arterial compliance and haemostatic factors. The aim of this thesis was to examine the effects of several food components, particularly soybean and monounsaturated fat (MUFA), on CHD risk factors through 3 carefully controlled dietary interventions, and a cross-sectional study. A randomised crossover dietary intervention study was conducted in 42 healthy males to investigate the effect on CHD risk factors of replacing lean meat with tofu, a soybean product regularly consumed by Asian populations, while controlling all other dietary factors. The tofu diet resulted in significantly lower total cholesterol and triacylglycerol levels compared to the lean meat diet, and LDL particles that were more resistant to in vitro oxidative modification. However, insulin, fibrinogen, factor VII, and lipoprotein (a) were not significantly different on the 2 diets. A postprandial study was subsequently conducted to investigate any acute effects of a tofu test meal on the oxidative modification of LDL in 16 male subjects. There was no significant difference between the susceptibility of LDL to oxidative modification before and after the tofu meal. Twenty eight healthy subjects completed a separate randomised crossover dietary intervention comparing a high MUFA fat diet, using an Australian high oleic sunflower oil, with a low fat, high carbohydrate diet on CHD risk factors. The high MUFA oil diet significantly increased high density lipoprotein cholesterol compared to the low fat diet as well as producing LDL that were more resistant to oxidative modification. Neither the size of the LDL particle nor arterial compliance were significantly different on the 2 diets. Twelve matched pairs of vegetations and omnivores were also studies to compare the habitual diet of a low and higher risk population group, to compare their risk factors and identify dietary constituents that may explain the differences. The vegetarians consumed less saturated fat (SFA) and dietary cholesterol while consuming more polyunsaturated fat, dietary fibre and vitamin E compared to omnivores. The vegetarians had lower total cholesterol, LDL cholesterol and triacylglycerol levels compared to the omnivores and had LDL particles that were more resistant to in vitro oxidation. These findings contribute to our knowledge about the dietary constituents that can alter some CHD risk factors in healthy subjects, and which could reduce the risk of developing CHD. Investigations in high risk groups might reveal even more benefits.

Стилі APA, Harvard, Vancouver, ISO та ін.

Shaw, I., BS Shaw, and GA Brown. "Influence of strength training on cardiac risk prevention in individuals without cardiovascular disease." African Journal for Physical, Health Education, Recreation and Dance, 2009. http://encore.tut.ac.za/iii/cpro/DigitalItemViewPage.external?sp=1001650.

Повний текст джерела

Анотація:

Abstract It has widely been shown that exercise, particularly aerobic exercise, has extensive cardioprotective benefits and is an important tool in the prevention of coronary heart disease (CHD). The present investigation aimed to determine the multivariate impact of strength training, designed to prevent the development of CHD, on the Framingham Risk Assessment (FRA) score. Twenty-eight healthy untrained men with low CHD risk (mean age 28 years and 7 months) participated in an eight-week (3- d/wk) strength training programme. Self-administered smoking records, resting blood pressures, total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), FRA scores and absolute 10-year risks for CHD were determined at the pre-test and post-test. After the eight-week period, no significant (p > 0.05) differences were found in number of cigarettes smoked daily, systolic blood pressure, TC, HDLC, FRA scores and absolute 10-year risks for CHD in both the strength-trained (n = 13) and non-exercising control (n = 15) groups. The data indicate that strength training did not reduce the risk of developing CHD and absolute 10-year risk for CHD as assessed by the FRA score.

Стилі APA, Harvard, Vancouver, ISO та ін.

Wrigley, Martha J. "Engaging families with a premature family history of heart disease : a primary prevention study for coronary heart disease." Thesis, University of Southampton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.485524.

Повний текст джерела

Анотація:

This thesis focuses upon a preventative approach for people with a familial history of premature coronary heart disease. The research study had two aims; firstIy to understand the experience of individuals when their parent or sibling had been diagnosed with heart disease; secondly to develop and evaluate a primary prevention health promotion programme for these people. The thesis provides unique insight into their personal experiences of living with tIris familial diagnosis and gives details of how this population can be identified and involved successfully in a health promotion programme. The study was conducted in a district general hospital; 28 people were recruited of whom 20 participants completed the two year study. Narrative interviews were conducted at the beginning and end of the study, providing insight into people's personal experience. Salutogenesis is the theoretical framework in which the narratives are discussed; from these health resources are identified which can enhance people's progress and maintenance for a healthy lifestyle. The health promotion programme has established, developed and evaluated a nurseled and doctor supported primary pjevention strategy. Education and support was provided in the programme for individuals and families. The participants' physical and behavioural changes were reviewed six monthly, for two years. People are aware of risk factors associated with heart disease, but still seek professional support and advice in relation to their own lifestyle and behaviour. Individual lifestyle changes were achieved by most participants, which translated into significant findings for blood pressure and alcohol consumption; positive changes were seen in physical activity, smoking, diet and psychosocial stress. There were no improvements in lipid profiles. The need for a preventatiye approach in health care, which includes primordial and primary prevention for heart disease, is discussed. The issues in this thesis are reflective upon current government focus to develop preventative health services which actively engage with people as integral to this process. The thesis discusses coronary heart disease, the roles of prevention and health promotion, and identifies health resources for people at high-risk of future cardiovascular problems.

Стилі APA, Harvard, Vancouver, ISO та ін.

Veroni, Margherita. "The use of pharmacotherapies in the secondary prevention of coronary heart disease." University of Western Australia. School of Population Health, 2006. http://theses.library.uwa.edu.au/adt-WU2006.0029.

Повний текст джерела

Анотація:

[Truncated abstract] Background: This thesis examines pharmacotherapy use in the secondary prevention of coronary heart disease. It includes antiplatelet agents, beta-blockers, statins and ACE inhibitors, all shown in landmark clinical trials and meta-analyses to reduce the risk of cardiac events in patients with known coronary disease. Underuse of effective preventive therapies represents a lost opportunity to reduce mortality and morbidity. Overseas studies have shown significant underuse of effective therapies at the time of hospital discharge following an acute event and later in ambulatory care. Australian data on prescribing practices following an acute coronary event and, ongoing use in ambulatory care are sparse. Aims: The aim of this thesis was to quantify the prescription of known effective therapies at the time of hospital discharge following an acute coronary event and ongoing use in ambulatory care. A secondary aim was to identify barriers to optimal secondary prevention thus providing an evidential basis to recommend change. Methods: This was an observational study of a cohort of post-MI patients admitted to a tertiary and affiliate hospital in Perth, Western Australia. The continuum of care from the treatment plan at discharge through to the treatment regimen and risk factor management 12 months post-MI was examined. The intermediate step, communication about the treatment plan with the patient and the primary health care provider was also examined. The study involved a review of hospital medical records and follow-up questionnaires to patients and their general practitioners at 3 and 12 months post-MI. All post-myocardial patients were included in the analysis of prescriptions at discharge. The follow-up study included patients 80 years and younger with no terminal conditions. Patient interviews at 3 months and interviews and focus groups with key hospital staff provided qualitative data to inform the quantitative data.

Стилі APA, Harvard, Vancouver, ISO та ін.

Rees, Lois. "The provision of disease prevention services from community pharmacies." Thesis, University College London (University of London), 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.339279.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lalonde, Lyne. "Health-related quality of life measures in coronary heart disease prevention and treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0006/NQ44484.pdf.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Khatib, R. "Adherence to secondary prevention medicines by coronary heart disease patients : first reported adherence." Thesis, University of Bradford, 2012. http://hdl.handle.net/10454/5484.

Повний текст джерела

Анотація:

Background Non-adherence to evidence based secondary prevention medicines (SPM) by coronary heart disease (CHD) patients limits their expected benefits and may result in a lack of improvement or significant deterioration in health. This study explored self-reported non-adherence to SPM, barriers to adherence, and the perception that patients in West Yorkshire have about their medicines in order to inform practice and improve adherence. Methods In this cross-sectional study a specially designed postal survey (The Heart Medicines Survey) assessed medicines-taking behaviour using the Morisky Medicines Adherence 8 items Scale (MMAS-8), a modified version of the Single Question Scale (SQ), the Adherence Estimator (AE), Beliefs about Medicines Questionnaire(BMQ) and additional questions to explore practical barriers to adherence. Patients were also asked to make any additional comments about their medicines-taking experience. A purposive sample of 696 patients with long established CHD and who were on SPM for at least 3 months was surveyed. Ethical approval was granted by the local ethics committee. Results 503 (72%) patients participated in the survey. 52%, 34% and 11% of patients were prescribed at least four, three and two SPMs respectively. The level of non-adherence to collective SPM was 44%. The AE predicted that 39% of those had an element of intentional non-adherence. The contribution of aspirin, statins, clopidogrel, beta blockers, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) to overall non-adherence as identified by the SQ scale was 62%, 67%, 7%, 30%, 22% and 5%, respectively. A logistic regression model for overall non-adherence revealed that older age and female gender were associated with less non-adherence (OR = 0.96, 95% CI: 0.94, 0.98; OR = 0.56, 95% CI: 0.34, 0.93; respectively). Specific concern about SPM, having issues with repeat prescriptions and aspirin were associated with more non-adherence (OR = 1.12, 95% CI: 1.07, 1.18; OR = 2.48, 95% CI: 1.26, 4.90, OR = 2.22, 95% CI: 1.18, 4.17). Other variables were associated with intentional and non-intentional non-adherence. 221 (44%) patients elaborated on their medicines-taking behaviour by providing additional comments about the need for patient tailored information and better structured medicines reviews. Conclusions The Medicines Heart Survey was successful in revealing the prevalence of self-reported non-adherence and barriers to adherence in our population. Healthcare professionals should examine specific modifiable barriers to adherence in their population before developing interventions to improve adherence. Conducting frequent structured medicines-reviews, which explore and address patients' concerns about their medicines and healthcare services, and enable them to make suggestions, will better inform practice and may improve adherence.

Стилі APA, Harvard, Vancouver, ISO та ін.

Emberson, Jonathan Robert. "Within-person variation in coronary risk factors : implications for the aetiology and prevention of coronary heart disease." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1444402/.

Повний текст джерела

Анотація:

Epidemiological studies clearly demonstrate the importance of numerous risk factors for coronary heart disease (CHD), including blood lipids, blood pressure, cigarette smoking and physical inactivity. These factors are widely believed to account for only around 50% of CHD cases. However, "within-person" variation in coronary risk factors can affect the size and even direction of estimated aetiological relationships, and though these effects have been explored for the univariate relations of blood pressure and blood cholesterol, much uncertainty remains. In this thesis, data from the British Regional Heart Study, a prospective study of cardiovascular disease in middle-aged British men, is used to investigate the extent and effects of "within-person variation" in a range of coronary risk factors. The effects on estimated relations with CHD are examined and the combined importance of the major risk factors to CHD risk assessed. The potential effectiveness of different CHD prevention strategies, and the size and cause of social inequalities in CHD are also estimated. The findings reveal a high degree of within-person variation in both established and novel coronary risk factors. Taking within-person variation into account, CHD risk-relations for blood lipids, blood pressure, cigarette smoking and physical inactivity increase in magnitude though the estimated protective effect from moderate alcohol intake is reduced. After correction for within-person variation, blood cholesterol, blood pressure and cigarette smoking together account for at least 75 80% of CHD cases in British men. Moderate population-wide improvements in these risk factors could there fore greatly reduce population levels of CHD, while "high-risk" strategies, unless applied to a large proportion of the population, are likely to have only a limited effect. Narrow ing social inequalities in CHD would also have a comparatively modest effect on CHD compared with population-wide control of the key causal coronary risk factors.

Стилі APA, Harvard, Vancouver, ISO та ін.

裴中 and Zhong Pei. "Neuroprotection of melatonin in ischemic stroke models." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B31243526.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Coronary heart disease Victoria Prevention"

Brown, Don. Hyperlipidemia and prevention of coronary heart disease. Seattle, WA: Natural Product Research Consultants, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Authority, Northumberland Health. Northumberland coronary heart disease prevention strategy: 1992. Morpeth: Northumberland Health Authority, 1992.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Royal Colleges of Physicians of the United Kingdom. Committee on Health Promotion. Coronary heart disease prevention: Putting it intopractice. London: Faculty of Public Health Medicine of the Royal Colleges of Physicians of the United Kingdom, 1990.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Pain, Charles Hawkhurst. Coronary heart disease prevention: An ecological approach. Manchester: University of Manchester, 1990.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Coronary prevention: A clinical guide. Chicago: Year Book Medical Publishers, 1985.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Cohn, Peter F. Heart talk: Preventing and coping with silent and painful heart disease. Boston: Harcourt Brace Jovanovich, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tom, Heller, and Open University, eds. Coronary heart disease: Reducing the risk : a reader. Chichester [West Sussex]: Wiley, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Miller, J. M. T. 1944-, ed. 52 ways to prevent heart disease. Nashville: T. Nelson, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hofmann, Hubert, ed. Primary and Secondary Prevention of Coronary Heart Disease. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70296-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Michael, Miller. The practice of coronary disease prevention. Baltimore: Williams & Wilkins, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Coronary heart disease Victoria Prevention"

Duprez, Daniel. "Prevention of Coronary Artery Disease." In Coronary Heart Disease, 497–508. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-1475-9_29.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sherazi, Saadia, and Robert Block. "Coronary Artery Disease Prevention." In Manual of Heart Failure Management, 17–32. London: Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-185-9_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mulcahy, R. "The Role of the General Practitioner in the Prevention of Coronary Heart Disease." In Coronary Heart Disease, 27–57. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-010-9218-0_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

de Lorgeril, Michel, and Patricia Salen. "Dietary Prevention of Coronary Heart Disease." In Wild-Type Food in Health Promotion and Disease Prevention, 227–42. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-330-1_17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Schaefer, Ernst J., and Mariko Tani. "Nutrition and Coronary Heart Disease Prevention." In Dyslipidemias, 329–41. Totowa, NJ: Humana Press, 2015. http://dx.doi.org/10.1007/978-1-60761-424-1_19.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Patel, C. "Prevention Paradox in Coronary Heart Disease." In Biological and Psychological Factors in Cardiovascular Disease, 533–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71234-0_34.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

von der Lohe, Elisabeth. "Primary and Secondary Prevention of Coronary Heart Disease." In Coronary Heart Disease in Women, 145–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55553-4_8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rose, G. "Social Class and Coronary Heart Disease." In Primary and Secondary Prevention of Coronary Heart Disease, 44–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70296-9_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Puddu, P., and M. Muscari. "Therapy versus prevention of coronary heart disease." In Atherosclerosis and Cardiovascular Diseases, 163–70. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3205-0_20.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Houston, Mark C. "The Integrative Coronary Heart Disease (CHD) Prevention Program." In The Truth About Heart Disease, 219–76. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22808-22.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Coronary heart disease Victoria Prevention"

Holm, Jukka, Reijo Laaksonen, Paul Dendale, Cindel Bonneux, and Martijn Scherrenberg. "Creating Audio-Visual Content for a Personalized Prevention Programme in Coronary Heart Disease." In 2022 26th International Conference Information Visualisation (IV). IEEE, 2022. http://dx.doi.org/10.1109/iv56949.2022.00070.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Poniewierski, M., M. Barthels, and H. Poliwoda. "THE SAFETY AND EFFICACY OF A LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) IN THE PREVENTION OF DEEP VEIN THROMBOSIS IN MEDICAL PATIENTS: A RANDOMIZED DOUBLE-BLIND TRIAL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643224.

Повний текст джерела

Анотація:

The safety and efficacy of 2500 anti-Factor Xa U of a low molecular weight heparin (Kabi 2165, Fragmin) subcutaneously once a day, and 5000 IU of standard unfractionated Heparin (KabiVitrum, Stockholm) subcutaneously twice daily as thromboprophylaxis was compared in 200 medical patients in a randomized double blind trial. According to the risk of DVT the patients were stratified before randomization in a high and low risk group. The high risk group consisted of 100 patients mainly with malignant diseases and/or previous history of thromboembolism, the low risk group of 100 patients with mainly myocardial infarction and/or coronary heart disease. The prophylaxis was given for seven to ten days. In 192 consecutive patients the clinical status and thermographic screening for DVT (leg temperature profiles, DeVeTherm) were daily evaluated. In two cases of suspected DVT and one case of suspected PE, the following phlebography or pulmonary scintigraphy were found to be negative. In the high risk group, one patient treated with Fragmin having a central venous catheter developed on day 10 symptoms of an arm vein thrombosis. There were no bleeding complications observed in either of the two treatment groups. Two patients with trombocytopenia (25.000 and 22.000/pl) due to chemotherapy and underlying malignant disease were successfully treated with Fragmin without developing any bleeding complications. In eight patients during Fragmin prophylaxis invasive diagnostic methods as heart catheterization, gastroscopy, bronchoscopy or spinal puncture were performed without noticing any bleeding events. 2500 anti-Factor Xa U of Fragmin gave plasma levels by anti-Factor Xa assay (S-2222, Kabi) of mean 0,1 U/ml when blood was sampled three to four hours after the subcutaneus application. There was no accumulation during the treatment periode observed.This study suggests that 2500 anti-Factor Xa U of Fragmin once daily is as safe and effective as 5000 IU of standard heparin twice daily in these medical patients. Especially in patients who need prophylaxis for a long time eg. with malignant disease, the once daily injection is welcomed.

Стилі APA, Harvard, Vancouver, ISO та ін.

García Mozos, Luis, Devonjit Saroya, Yannick Roelvink, Naël dos Santos D'Amore, Stefano Gabetti, Jorge Galván Lobo, Catarina Lobo, et al. "Artery in Microgravity (AIM): Assembly, integration, and testing for a student payload for the ISS." In Symposium on Space Educational Activities (SSAE). Universitat Politècnica de Catalunya, 2022. http://dx.doi.org/10.5821/conference-9788419184405.097.

Повний текст джерела

Анотація:

The Artery in Microgravity (AIM) project was the first experiment to be selected for the “Orbit Your Thesis!” programme of the European Space Agency Academy. It is a 2U cube experiment that will be operated in the International Commercial Experiment (ICE) Cubes facility onboard the International Space Station. The experiment is expected to be launched on SpaceX-25 in mid-2022. The project is being developed by an international group of students from ISAE-SUPAERO and Politecnico di Torino. The objective of the experiment is to study haemodynamics in the space environment applied to coronary heart disease. The outcomes of this testbench will contribute to understanding the effects of radiation and microgravity on the circulatory system of an astronaut, specifically the behaviour in long-term human spaceflight. It will also help to ascertain the feasibility of individuals suffering from this kind of disease going to space someday. The cornerstones of the experiment are two models of 3D-printed artificial arteries, in stenotic and stented conditions respectively. Blood-mimicking fluid composed of water and glycerol is circulated through the arteries in a closed hydraulic loop, and a red dye is injected for flow visualisation. Drops of pressure and image analysis of the flow will be studied with the corresponding sensors and camera. The pH of the fluid will also be monitored to assess the effect of augmented radiation levels on the release of particles from the metallic stent. Some delays were experienced in the project due to the COVID-19 pandemic and to implement design improvements. Improvements were made to several aspects of the design including mechanics (e.g. remanufacturing the reservoir with surface treatment against corrosion, leak prevention measures), software (e.g. upgrading to Odroid-C4 and migrating the code to Python), and electronics (e.g. several iterations of the interface PCB design). This iterative process of identifying areas of concern and designing and implementing solutions has resulted in many lessons learned. The paper will outline in detail Phase D – Qualification and Production of the AIM experiment cube, with special insight on the implementation of the improvements. Previously, at the Symposium on Space Educational Activities in 2019 in Leicester, the initial phases of the design and development of the cube were presented. This year, the final flight model and the results of validation testing before launching on SpaceX-25 are presented. Lessons learned throughout the course of the project are also highlighted for students embarking on their own space-related educational activities.

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Coronary heart disease Victoria Prevention"

Xie, Bo, Xiaojiao Cui, Hao Wang, Fuqiang Liu, Fang Qin, Jun Zhang, and Xiaoqing Yi. Prevention of contrast-induced acute kidney injury by probucol combined with hydration in patients with coronary heart disease: a systematic review and meta analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0157.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wei, Dongmei, Yang Sun, and Hankang Hen. Effects of Baduanjin exercise on cardiac rehabilitation after percutaneous coronary intervention: A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0080.

Повний текст джерела

Анотація:

Review question / Objective: Can Baduanjin exercise improve the cardiac rehabilitation of patients with coronary artery disease after percutaneous coronary artery surgery? Condition being studied: Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the single most common cause of death globally, with 7.4 million deaths in 2013, accounting for one-third of all deaths (WHO 2014). PCI has been shown to be effective in reducing mortality in patients with CHD. During follow-up, it has been shown that the benefits of PCI can be offset by the significant risks of coronary spasm, endothelial cell injury, recurrent ischemia, and even restenosis or thrombus. Numerous guidelines endorse the necessity for cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndrome and for patients following PCI. Baduanjin have been widely practised in China for centuries, and as they are considered to be low risk interventions, their use for the prevention of cardiovascular disease is now becoming more widespread. The ability of Baduanjin to promote clinically meaningful influences in patients with CHD after PCI, however, still remains unclear.

Стилі APA, Harvard, Vancouver, ISO та ін.

Treadwell, Jonathan R., James T. Reston, Benjamin Rouse, Joann Fontanarosa, Neha Patel, and Nikhil K. Mull. Automated-Entry Patient-Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes. Agency for Healthcare Research and Quality (AHRQ), March 2021. http://dx.doi.org/10.23970/ahrqepctb38.

Повний текст джерела

Анотація:

Background. Automated-entry consumer devices that collect and transmit patient-generated health data (PGHD) are being evaluated as potential tools to aid in the management of chronic diseases. The need exists to evaluate the evidence regarding consumer PGHD technologies, particularly for devices that have not gone through Food and Drug Administration evaluation. Purpose. To summarize the research related to automated-entry consumer health technologies that provide PGHD for the prevention or management of 11 chronic diseases. Methods. The project scope was determined through discussions with Key Informants. We searched MEDLINE and EMBASE (via EMBASE.com), In-Process MEDLINE and PubMed unique content (via PubMed.gov), and the Cochrane Database of Systematic Reviews for systematic reviews or controlled trials. We also searched ClinicalTrials.gov for ongoing studies. We assessed risk of bias and extracted data on health outcomes, surrogate outcomes, usability, sustainability, cost-effectiveness outcomes (quantifying the tradeoffs between health effects and cost), process outcomes, and other characteristics related to PGHD technologies. For isolated effects on health outcomes, we classified the results in one of four categories: (1) likely no effect, (2) unclear, (3) possible positive effect, or (4) likely positive effect. When we categorized the data as “unclear” based solely on health outcomes, we then examined and classified surrogate outcomes for that particular clinical condition. Findings. We identified 114 unique studies that met inclusion criteria. The largest number of studies addressed patients with hypertension (51 studies) and obesity (43 studies). Eighty-four trials used a single PGHD device, 23 used 2 PGHD devices, and the other 7 used 3 or more PGHD devices. Pedometers, blood pressure (BP) monitors, and scales were commonly used in the same studies. Overall, we found a “possible positive effect” of PGHD interventions on health outcomes for coronary artery disease, heart failure, and asthma. For obesity, we rated the health outcomes as unclear, and the surrogate outcomes (body mass index/weight) as likely no effect. For hypertension, we rated the health outcomes as unclear, and the surrogate outcomes (systolic BP/diastolic BP) as possible positive effect. For cardiac arrhythmias or conduction abnormalities we rated the health outcomes as unclear and the surrogate outcome (time to arrhythmia detection) as likely positive effect. The findings were “unclear” regarding PGHD interventions for diabetes prevention, sleep apnea, stroke, Parkinson’s disease, and chronic obstructive pulmonary disease. Most studies did not report harms related to PGHD interventions; the relatively few harms reported were minor and transient, with event rates usually comparable to harms in the control groups. Few studies reported cost-effectiveness analyses, and only for PGHD interventions for hypertension, coronary artery disease, and chronic obstructive pulmonary disease; the findings were variable across different chronic conditions and devices. Patient adherence to PGHD interventions was highly variable across studies, but patient acceptance/satisfaction and usability was generally fair to good. However, device engineers independently evaluated consumer wearable and handheld BP monitors and considered the user experience to be poor, while their assessment of smartphone-based electrocardiogram monitors found the user experience to be good. Student volunteers involved in device usability testing of the Weight Watchers Online app found it well-designed and relatively easy to use. Implications. Multiple randomized controlled trials (RCTs) have evaluated some PGHD technologies (e.g., pedometers, scales, BP monitors), particularly for obesity and hypertension, but health outcomes were generally underreported. We found evidence suggesting a possible positive effect of PGHD interventions on health outcomes for four chronic conditions. Lack of reporting of health outcomes and insufficient statistical power to assess these outcomes were the main reasons for “unclear” ratings. The majority of studies on PGHD technologies still focus on non-health-related outcomes. Future RCTs should focus on measurement of health outcomes. Furthermore, future RCTs should be designed to isolate the effect of the PGHD intervention from other components in a multicomponent intervention.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!